Mod GRF 1–29 · tetra-substituted GHRH analog
CJC-1295 (no DAC)
Cited range Short-acting GHRH
What it is
CJC-1295 without Drug Affinity Complex is a modified GHRH (1–29) fragment (also sold as Mod GRF 1–29). The four substitutions improve enzymatic stability versus native GHRH while keeping a short pulse.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- Also called Mod GRF 1-29. A short GHRH analog meant to make a clean GH pulse when you inject it.
- Best thought of as the “on” switch next to ipamorelin: one asks, one amplifies.
- Cited aims: sleep, recovery, body-composition support through your own GH.
- Because it is short-acting, timing (often evening) shows up in every community write-up.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
It binds pituitary GHRH receptors and elicits a GH pulse. Without DAC it does not albumin-bind for multi-day coverage, so sources describe multiple daily pulses rather than a weekly depot.
Possible side effects / caveats
Class effects of GH secretagogues: water retention, joint stiffness, tingling, possible insulin-resistance pressure if GH stays high. Flushing can occur. Vial labeling often confuses “CJC-1295” with the DAC version — they are not interchangeable.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Cited range | 100 mcg per pulse | 1–3× daily SC | Most repeated secondary figure |
| Cited stack | 100 mcg + 100–200 mcg ipamorelin | Same sitting | GHRH + GHRP co-pulse pattern |